Havana, Mar 25 (Prensa Latina) More than 13,000 Cuban workers from the health and biopharmaceutical sectors have been immunized with the first dose of the Soberana 02 Covid-19 vaccine candidate.
‘The intervention trial involving @MINSAPCuba and @BioCubaFarma workers, more than 13,000 with the first dose of the Soberana 02 vaccine candidate, makes progress. #MasQueUnaVacuna (MoreThanAVaccine), a country’, Cuban First Deputy Prime Minister Roberto Morales Ojeda wrote on his Twitter account.
The volunteers are participating in the intervention trial that started on Monday and involves 150,000 subjects to evaluate the effects of the vaccine in population sectors with a high risk of contagion, disease and spreading of the pandemic. The process, which is common to epidemiological clinical trials, will study the effectiveness and impact of the product designed by the Finlay Vaccine Institute (IFV) of Cuba in people exposed to the SARS-CoV-2 coronavirus, which causes Covid-19, in real situations of community contagion.
In a controlled way and without a placebo, the study involves 70,000 workers from the scientific pole and the health sector in Havana, where Phase III of clinical trial of the Soberana 02 vaccine is taking place with the participation of 44,010 subjects from eight municipalities.
The first volunteers who joined the intervention trial were workers from the Genetic Engineering and Biotechnology Center (CIGB) and the IFV.